PEMBROLIZUMAB
Manner of administration:Injection
Restriction (Streamlined authority code: 18373)
Indication: Stage IV (metastatic) non-small cell lung cancer (NSCLC)
Treatment phase: Initial treatment - 3 weekly treatment regimen
Restriction (Streamlined authority code: 13432)
Indication: Stage IV (metastatic) non-small cell lung cancer (NSCLC)
Treatment phase: Continuing treatment - 3 weekly treatment regimen
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 200 mg | # of repeats: 6 | DPMA: $7,503.74 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Keytruda
(pembrolizumab 100 mg/4 mL injection, 4 mL vial)
|
||||
